91 results
Page 4 of 5
8-K
EX-99.1
r88b9z
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
sh7 a1odt32ydpw1c6e
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
EX-99.1
m6x7lqm5
5 Nov 20
Sutro Biopharma Reports Third Quarter 2020 Financial Results
7:05am
8-K
EX-99.1
dakw3cbk x5t9kw
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
424B5
03f ts74ape01bp622x
12 May 20
Prospectus supplement for primary offering
5:02pm
8-K
EX-99.1
57nbr
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
424B5
p0xzjh
11 May 20
Prospectus supplement for primary offering
4:12pm
8-K
EX-99.1
98lxr1
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
rowfks54e gl4vyzeper
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
98ybwb
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
EX-99.1
bpo9xpu2mo f1g
8 Nov 19
Sutro Biopharma Reports Third Quarter 2019 Financial Results
8:00am
8-K
EX-99.1
6xg 1gri2
30 Oct 19
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
12:00am
424B5
i9fv3 hz37cht6
11 Oct 19
Prospectus supplement for primary offering
4:22pm
S-3
p0dg3i0x1mmids3
4 Oct 19
Shelf registration
4:06pm